Drug Topics
OCTOBER 14, 2024
Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.
Pharmacy Times
OCTOBER 14, 2024
The lawsuit alleges that the action was taken without the required notice and disputes the agency’s warning of “localized supply disruption,” while calling for more transparency.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 8, 2024
Florida-based pharmacist Brad Phillips, PharmD, BCACP, speaks to the importance of pre-planning, emergency refills, medication storage, and post-storm safety measures to ensure medication security during hurricanes.
Pharmacy Times
OCTOBER 12, 2024
High-resolution scans can provide a picture of a patient’s brain that typical MRIs cannot, allowing for more detailed insights into the neurological effects of COVID-19.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 13, 2024
SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions, according to a person familiar with the situation and employee posts on social media. It is the latest in a series of retrenchments by high-profile gene-editing companies. A spokesperson for SalioGen declined to comment.
Fierce Healthcare
OCTOBER 11, 2024
This story was reported in partnership with Uncloseted Media, a nonpartisan, investigative, LGBTQ | Ending the HIV epidemic hinges on both treatment and prevention, particularly through access to PrEP. For at-risk individuals living in the U.S. South—where HIV is a daunting reality—PrEP use is very low compared to the number of new HIV cases.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
OCTOBER 8, 2024
Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.
STAT
OCTOBER 11, 2024
The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, from its shortage list, and, for the time being, would not pursue regulatory action against certain compounding pharmacies making copies of the drugs. The decision, disclosed in a court filing, marked a stark reversal.
Fierce Healthcare
OCTOBER 11, 2024
Wolters Kluwer Health, a big player in clinical decision support solutions, is teaming up with Abridge to integrate UpToDate into its AI-based medical note-taking tool. | Wolters Kluwer Health, a big player in clinical decision support solutions, is teaming up with Abridge to integrate UpToDate into its AI-based medical note-taking tool.
Fierce Pharma
OCTOBER 8, 2024
With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.” In declaring the end of the shortage, the FDA has halted the ability of compounding pharmacies to manufacture the in-demand products.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
OCTOBER 11, 2024
Individuals living in rural areas can benefit from pharmacy-based pre-exposure prophylaxis programs.
Pharmacy Times
OCTOBER 11, 2024
This approval marks the first and only anti-tissue factor pathway inhibitor approved in the US for the treatment hemophilia A or B, and the first approved hemophilia treatment to be administered via a pre-filled, auto-injector pen.
STAT
OCTOBER 11, 2024
Since the Nobel Prizes were created in 1901, just 24 women have received awards in the sciences. This year, that number stayed the same: All seven laureates in physics , chemistry , and physiology or medicine were men. Some scientists have expressed frustration about the lack of women in this year’s awardees, particularly the omission of two women who contributed to the work honored for the prize in physiology or medicine.
Fierce Healthcare
OCTOBER 10, 2024
Intravenous fluid shortages appear to be affecting the majority of the nation’s healthcare providers, who as a result are already beginning to cancel procedures, survey data published Thursday show | Premier said 86% of its provider members are reporting shortages, and more than half have less than 10 days supply on hand. Respondents also said they were beginning or considering procedure cancellations, and have begun receiving solicitations from "unapproved, gray market suppliers.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
OCTOBER 14, 2024
Damage to a Baxter manufacturing facility caused by Hurricane Helene, which rolled across the east US a couple of weeks ago, has led to shortages in some critical medicines.The plant in North Cove, North Carolina, was severely affected by flooding and had to be shut down at the end of September. It is Baxter's biggest manufacturing site and is also the largest supplier of intravenous and peritoneal dialysis solutions to the US market.
Drug Topics
OCTOBER 9, 2024
Current rules governing lawsuits must be revisited to strike a balance between legitimate and frivolous legal actions against health care providers.
Pharmacy Times
OCTOBER 11, 2024
The exemption allows more time for partners to adhere to enhanced distribution security requirements in the Food, Drug, & Cosmetics Act and prevents possible supply chain disruptions.
STAT
OCTOBER 11, 2024
Recently, California Gov. Gavin Newsom granted $130.7 million for local governments addressing homelessness, including clearing encampments. It comes in the wake of a June Supreme Court ruling that gave cities full authority to implement and enforce policies that would allow them to clear encampments as they see fit. In early August, Newsom was even filmed removing homeless people’s belongings from public view in Mission Hills in Los Angeles County.
Fierce Healthcare
OCTOBER 9, 2024
The Centers for Medicare & Medicaid Services (CMS) released a list of prescription drugs it hopes to include in its new Medicare $2 Drug List Model, the agency announced Wednesday. | CMS is looking to further refine its new Medicare $2 Drug List Model to make prices more predictable for Part D beneficiaries.
Fierce Pharma
OCTOBER 11, 2024
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B.
Drug Topics
OCTOBER 10, 2024
Researchers analyzed the potential role of nonphysician health care providers to provide vaccine services outside of traditional health care settings.
Pharmacy Times
OCTOBER 8, 2024
Survodutide is a glucagon/glucagon-like peptide-1 (GLP-1_ receptor dual agonist that activates the glucagon and GLP-1 receptors to better control metabolic function.
STAT
OCTOBER 14, 2024
It may be time to add Covid-19 infection to the list of possible risk factors for developing type 2 diabetes at a young age. An observational study published Monday in JAMA Network Open found that children and adolescents were one-and-a-half times more likely to be diagnosed with the metabolic disorder in the months after having Covid-19 compared to similar kids who weathered other respiratory infections.
Fierce Healthcare
OCTOBER 9, 2024
Reports of recent cyberattacks and disruptions in patient care have ticked up among healthcare organizations since 2023, with the average attack bringing just under $1.5 million in operational disr | Ninety-two percent of polled healthcare IT and security practitioners said their organization had faced at least once cyberattack during the prior year.
PharmaVoice
OCTOBER 9, 2024
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
Pharmacy Times
OCTOBER 14, 2024
Artificial Intelligence (AI) is transforming drug development by automating routine tasks, enhancing clinical trials, and expediting drug discovery, ultimately leading to more personalized treatments.
STAT
OCTOBER 11, 2024
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire. Last week, the Food and Drug Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name Mounjaro for diabetes and Zepbound for obesity. The move was a clear warning to compounders that they can no longer make copycat versions of the drugs — a process that is only permitted when the medications are on
Fierce Healthcare
OCTOBER 10, 2024
Just 40% of Medicare Advantage prescription drug plans offered in 2025 achieved a score of four stars or higher, the Centers for Medicare & Medicaid Services (CMS) revealed Oct. 10. | It's harder than ever for Medicare Advantage plans to score well on star ratings. Here's how they performed for 2025.
Fierce Pharma
OCTOBER 8, 2024
Editor's Note: Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub in Tampa, Florida, in 2021—is setting out to bolster emergency services, pool donations and ease medical supply needs as Hurricane Milton touches down this week.
Drug Topics
OCTOBER 14, 2024
Research presented at ACCP 2024 found that addiction medicine consult services could help increase medication for opioid use disorder initiation.
Pharmacy Times
OCTOBER 11, 2024
Female and older patients had a greater incidence of herpes zoster ophthalmicus and were more likely to develop ocular complications.
STAT
OCTOBER 11, 2024
The 2024 Nobel Prizes will be remembered as the year that artificial intelligence took the awards by storm. The physics prize this week was awarded to two scientists, John Hopfield and Geoffrey Hinton, who laid the groundwork for the field of machine learning. The next day, the chemistry prize went to a trio of researchers whose work built on Hopfield and Hinton’s principles, developing AI models that predict the structure of proteins and design entirely new ones.
Fierce Healthcare
OCTOBER 15, 2024
Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a ro | Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a rocky fiscal 2024.
Fierce Pharma
OCTOBER 10, 2024
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio. | As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio.
Expert insights. Personalized for you.
123 
Let's personalize your content